Ardelyx, Inc. (ARDX)
$
5.92
+0.15 (2.53%)
Key metrics
Financial statements
Free cash flow per share
-0.2288
Market cap
1.3 Billion
Price to sales ratio
3.3614
Debt to equity
1.3457
Current ratio
4.4129
Income quality
0.9483
Average inventory
23.7 Million
ROE
-0.3691
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines aimed at treating various gastrointestinal and cardiorenal conditions both in the United States and internationally. The company's lead product candidate, tenapanor, has successfully completed Phase III clinical trials for treating patients suffering from irritable bowel syndrome with constipation and is also undergoing Phase III trials to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD) undergoing dialysis, a condition known as hyperphosphatemia. Ardelyx is additionally developing RDX013, a potassium secretagogue designed to address elevated serum potassium levels, or hyperkalemia, which is particularly relevant for certain patients with kidney or heart disorders. Furthermore, RDX020 is being investigated as an early-stage program targeting metabolic acidosis, a serious electrolyte imbalance affecting patients with CKD. The company has established collaborations with Kyowa Kirin for development in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. for China, and Knight Therapeutics, Inc. in Canada for commercializing tenapanor in those regions. The company's financial metrics show that the EBITDA is -$16,713,000.00 a key indicator of the company's operational profitability, while the gross profit stands at $283,059,000.00 highlighting its earnings from core operations. The weighted average number of diluted shares outstanding is 235,233,000.00 which reflects potential dilution effects, and the company reported depreciation and amortization expenses of $2,063,000.00 illustrating the wear and tear of its assets. Ardelyx’s stock is identified with the symbol 'ARDX' in the market. Investors may find the stock appealing, as it is affordable at $6.21 making it suitable for budget-conscious individuals. The stock boasts a high average trading volume of 3,465,961.00 indicating strong liquidity and interest from the market. With a market capitalization of $1,417,645,931.00 Ardelyx is classified as a small-cap player, which often indicates growth potential. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth in the Healthcare sector. This positioning enhances its ability to attract attention from both investors and collaborators in the field of biopharmaceuticals.
Is Ardelyx, Inc. (ARDX) a good investment?
Investing in Ardelyx, Inc. (ARDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Ardelyx, Inc. (ARDX)'s stock forecast?
Analysts predict Ardelyx, Inc. stock to fluctuate between $3.21 (low) and $6.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ardelyx, Inc.'s market capitalization?
As of 2025-12-04, Ardelyx, Inc.'s market cap is $1,417,645,931, based on 239,467,218 outstanding shares.
How does Ardelyx, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Ardelyx, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ardelyx, Inc. (ARDX) stock?
To buy Ardelyx, Inc. (ARDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ARDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Ardelyx, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ardelyx, Inc. stock ever split?
Ardelyx, Inc.'s last stock split was 4:1 on 2021-07-20.
How did Ardelyx, Inc. perform in the last earnings report?
Revenue: $333,615,000 | EPS: -$0.17 | Growth: -43.33%.
Where can I find Ardelyx, Inc.'s investor relations reports?
Visit https://www.ardelyx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ardelyx, Inc.?
You can explore historical data from here
What is the all-time high and low for Ardelyx, Inc. stock?
All-time high: $10.13 (2024-02-12) | All-time low: $0.49 (2022-06-16).
What are the key trends affecting Ardelyx, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing commercial and pipeline development.
seekingalpha.com
Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supporting what should be renewed investor confidence in ARDX. Updated analysis highlights Ardelyx's improving fundamentals and potential for further upside following the latest quarterly report.
seekingalpha.com
Ardelyx, Inc. ( ARDX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Christopher Raymond Joohwan Kim Roanna Ruiz Dennis Ding Thomas Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Joseph Thome - TD Cowen, Research Division Julian Harrison - BTIG, LLC, Research Division Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Daz Patel Presentation Operator " Caitlin Lowie Vice President of Corporate Communications & Investor Relations " Michael Raab President, CEO & Director " Eric Foster Chief Commercial Officer " Justin Renz Chief Financial & Operations Officer " Christopher Raymond " Raymond James Joohwan Kim " Citi Roanna Ruiz " Leerink Partners Dennis Ding " Jefferiesruiz Thomas " Wedbush Securities Matthew Caufield H.C.
zacks.com
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.
globenewswire.com
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 30, 2025, at 4:30 p.m.
globenewswire.com
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a $36 billion commercial business.
seekingalpha.com
Ardelyx, Inc. (NASDAQ:ARDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Robert Klingenberger Presentation Robert Klingenberger All right. Great. Good morning.
seekingalpha.com
Ardelyx, Inc. (NASDAQ:ARDX ) Citi's Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst We're going to start the afternoon session. I'm Yigal Nochomovitz, biotech analyst at Citi.
seekingalpha.com
The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-year net sales guidance range for the product by $10 million at the mid-point. Xphozah is showing resilience post-Medicare access loss, with commercial sales stabilizing and the product seeing increased demand and sales growth in Q2 versus Q1.
See all news
